Svedberg Open
DISSEMINATION OF KNOWLEDGE

International Journal of Artificial Intelligence and Machine Learning

Publisher's Home Page: https://www.svedbergopen.com/



Research Paper Open Access

Artificial Intelligence-Enabled Adaptive Patient Education in Pharmacy: A Workflow-Centered Model For Patient Engagement, Medication Adherence, and Clinical Outcomes

Sonam Kumari[1] , Sai Teja Rayabarapu[2] , Albin Joseph[3]

[1]FT MBA in Management Science, Graduation, Senior Manager Pharmacy Strategy AI Innovation
Questrom School of Business, Boston University, Boston, Massachusetts, USA. Email: ksonam827@gmail.com, ORCID ID: 0009-0008-1792-7888
[2]Independent Healthcare Researcher, Dallas Texas USA. Email: saitejarayabarapu@gmail.com ORCID: 0009-0002-3774-0697
[3]MS in Software Engineering Independent Researcher – Computer Science & Artificial Intelligence
Fremont California USA. Email: albin2Joseph@gmail.com , ORCID ID: 0009-0008-5086-6730

Abstract
Non-adherence to medicines is a widespread health problem worldwide and is a major contributor to poor clinical outcomes and to health care costs when managing chronic non-communicable diseases. Although effective, traditional pharmacist-led interventions are often limited by significant workflow challenges, staffing issues and the static nature of traditional teaching materials. However, artificial intelligence offers a sophisticated, data-driven alternative to optimize these traditional strategies in a proactive, personalised and highly scalable way in medication management. The present study aims to examine the possibility of implementing an adaptive patient education platform integrated into the clinical pharmacy workflow that could increase patient engagement, adherence, and improve specific clinical parameters using AI technology. A twelve-month-long longitudinal randomized controlled trial was carried out in adults with both type 2 diabetes and hypertension. The intervention was based on the use of natural language processing and machine learning algorithms for tailored learning content based on the Patient Activation Measure. Analysis of the results showed that the use of AI was statistically significantly associated with higher Patient Activation Measure (PAM) scores and greater Proportion of Days Covered (PDC) when compared with standard care. In addition, significant reductions in glycated hemoglobin and SBP measures were seen. In conclusion, the use of AI models that are workflow oriented can significantly complement current clinical practice in pharmacies, with the aim of fostering ongoing behavioral change and improved clinical results.

Keywords: Artificial Intelligence, Patient Education, Medication Adherence, Pharmacy Workflow, Patient Activation Measure, Clinical Outcomes.

Introduction

Medication adherence, which is the proper use of prescribed medications, is considered a standard, essential and necessary part of the care for chronic diseases, and is a key determinant of chronic disease outcomes over time and the overall effectiveness of health care systems around the world. In recent epidemiological literature, medication non-adherence has been consistently recognized as a key contributor to preventable morbidity, mortality and unnecessary healthcare utilization. In developed countries, the non-adherence rate to chronic disease treatment is generally thirty percent to fifty percent, and is often even worse in resource-poor or developing regions, where access to health care is limited (Mathew et al., 2020). These systemic issues with therapeutic compliance result in suboptimal clinical outcomes, speed of disease progression and often inappropriate and escalating treatment modifications by prescribing physicians. In the context of the pharmaceutical care, managing these complexities at an individual level may be very insufficient with conventional interventions. All these factors make it impossible to provide truly personalized care, as the number of patients is very large, the consultation time is limited, and the content of printed patient education materials is static (Dima et al., 2024). Therefore, the need exists to explore other, technologically viable,

options, that can be easily incorporated into the challenging and fast-paced working culture of contemporary clinical and community pharmacies.

In advanced pharmacy practice, the integration of AI has become a game-changer that promises to revolutionize the landscape of medication adherence interventions, offering unprecedented opportunities for modernization and enhancement. Artificial Intelligence applications have the unprecedented ability to analyze large and complex biomedical data in order to gain a wealth of information about patient behavior, demographic characteristics and the detailed history of medications (Ghozali & Forthwengel, 2024). The technological capabilities enable systematic development of adaptive patient education models that can dynamically adjust to the cognitive needs, different levels of health literacy and different psychological barriers of individual patients. There are other digital health interventions, but AI-powered platforms can predict the likelihood of non-adherence much more accurately than the traditional ones, even before it happens, which is why they can be used to intervene proactively instead of waiting for the clinical deterioration to occur (Ridho et al., 2022). Embedded in the existing pharmacy workflow, these intelligent, responsive systems have the potential to transform patient-provider communication, moving beyond one size fits all counseling to precision-based pharmaceutical care.

Though the potential application of AI in clinical practice is very promising, the successful and sustainable implementation in the clinic is rarely reported in peer-reviewed literature, especially in the area of direct, long-term effects on measurable clinical outcome and workflow optimization. The pharmacy workforce is well suited and ideally placed in this important role as it is responsible for deployment, validation and maintenance of clinical decision support systems and patient facing AI educational tools. Yet, the integration of these sophisticated tools is often significantly impeded by legitimate worries about workflow disruption, compliance with stringent privacy laws, bias in algorithms, and the risk of de-personalizing the crucial connection between patients and pharmacists (Gupta & Mehta, 2022). A successful AI system that can help to improve the quality of patient care will be carefully designed with a mind to human-centered design principles and will be designed to complement, not replace, routine pharmacy functioning. The impact of a true workflow-based model is expected to greatly reduce the huge administrative and educational burden currently being shouldered by pharmacists. It automatically classifies high-risk patients that need intensive and direct clinical intervention and enables autonomous management of routine educational reinforcement for the lower-risk patient population (Zhang et al., 2023).

The overall aim of this large-scale research project is to systematically assess clinical and behavioral effectiveness of an innovative, AI-driven adaptive patient education platform tailored for seamless integration into the usual workflow of the pharmacy. The study aims to conclusively measure the effects of a detailed, specifically diabetes and primary hypertension (DPH) targeted digital intervention by combining psychological engagement and behavioral adherence with a dynamic and machine learning supported nudge system.The study aims to measure the effect of a detailed, specifically targeted (for patients managing diabetes and primary hypertension, or DPH) digital intervention using a psychological engagement measure and a behavioral adherence measure, combined with a dynamic and machine learning driven educational nudge system. The Patient Activation Measure is a highly validated instrument that has been psychometrically and systematically evaluated and is highly reliable in quantifying patient knowledge, skill and confidence in managing their health independently (Hibbard et al., 2004). At the same time, the adherence to medications is objectively measured using the Proportion of Days Covered (PDC) measure, derived directly and precisely from records recorded in pharmacy-dispensing software. Moreover, the downstream clinical outcomes of the intervention are constantly monitored during the follow-up period, with the measurements of important physiological parameters, such as glycated hemoglobin and systolic blood pressure. The utility and necessity of automated and adaptive learning models in modern pharmacy practice will be confirmed, and statistically significant and clinically meaningful enhancements are expected for all evaluated domains compared to SoC after the targeted AI intervention.

Literature Survey

Over the last ten years, there has been a great deal of research and investment into the intersection of AI, digital health, and pharmaceutical care. The global digital medication adherence market has experienced exponential growth over the last few years and continues to grow on a regular basis, marking a significant shift in the approach to medication adherence from a generic to a far more personalized and data-driven approach, both within integrated health systems and independent clinical practices (Conway & Kelechi, 2017). O'Hara and colleagues (2022) conducted a thorough systematic review of the AI tools currently being used to enhance

medication adherence to identify four key, distinct modalities of intervention, including predictive analytics for accurate risk stratification, mobile health applications for ongoing behavioural reinforcement, smart pill dispensers that leverage Internet of Things (IoT) technology for real-time medication tracking, and conversational agents or virtual chatbots that are designed specifically for on-demand patient support. Of these different modalities, complex machine learning algorithms have consistently shown to be very effective with highly reliable results in the detection of hidden patterns that predict future therapeutic non-adherence. Recent studies have shown that the predictive algorithm can accurately identify individuals with high risk of missing doses of drugs for complex cardiometabolic conditions consistently at a rate of 70% to 80% (Husnawati et al., 2022). This predictive ability truly enables the clinical pharmacist to make the most of his or her clinical and temporal resources and concentrate his or her time on allotting intense, direct time to counseling only those at the highest risk, while the automated systems handle compliant patients and maintain them on board.

The role of conversational artificial intelligence (AI), such as advanced chatbots and virtual digital assistants, has been widely described in recent literature as a transformative tool to significantly improve patient education and engagement over time. A recent, thorough meta-analysis of artificial intelligence-based chatbots for the ongoing management of severe non-communicable diseases (NCDs) found that AI-chatbots could yield highly significant changes in adherence measures when AI software platforms were integrated with multidimensional clinical functions, including timely medication reminders, interactive health coaching, and real-time knowledge of patients' side-effects (Singh et al., 2024). In addition, it is also possible to implement advanced natural language processing algorithms to dynamically adapt patient education content and continuously rewrite, translate and adapt patient education so that it is comprehensively understood by patients, who are frequently confronted with complex diagnoses, treatment options and instructions for self-care. (Backes et al., 2021). This adaptive capacity is even more important for highly vulnerable population groups with limited health literacy, for which rigid, complex and highly clinical language can be a significant and insurmountable barrier for optimizing medication use. There is now good evidence that the use of specially designed AI tools can significantly lower the risk of dangerous self-medication errors, and can contribute to greatly improving overall patient satisfaction, by offering support that is available at all times, non-judgemental and very accessible and is not part of the traditional, time-limited clinical encounter (Hartani, 2022).

The Patient Activation Measure has quickly become a key, highly reliable measurement tool to capture the psychological aspects of chronic disease management, in-depth and rigorously testing the actual behavior of digital interventions. According to the behavioral sciences, patient activation refers to one's ability and desire (4) to assume a highly competent role in the management of a chronic health condition, without relying on others (Kearns et al., 2020). Significant and widely documented clinical evidence has now been published relating to higher patient activation levels and significantly better medication adherence rates across a range of diseases. Patients with a firm, empowered knowledge of their health conditions are naturally more likely to diligently follow the complex, multiple-drug regimen and be able to identify the early subtle signs of potentially life-threatening drug interactions before they lead to an acute hospital admission (Caballero et al., 2023). Clinical trials in different integrated pharmacy environments have consistently shown that customized and adaptive education programs based on the specific baseline activation of the patient produce significantly better behavioral outcomes when compared directly to general, non-spectrum education programs (Whalley Buono et al., 2017). The scale of this data is impressive, but when it comes to continually measuring, monitoring and reacting to changing levels of patient activation, traditional pharmacy workflows have a major operational blind spot that can be quickly closed by highly adaptive systems based on artificial intelligence.

To ensure the successful and sustainable integration of AI into the existing clinical pharmacy workflow, it is crucial to carefully consider the principles of human-computer interaction and highly restrict the operational constraints of AI systems. Yes, artificial intelligence (AI)-powered clinical decision support systems do significantly and measurably shorten the overall time spent on routine prescription processing, automated high-volume dispensing and routine clinical inquiry resolution (Hatzimanolis et al., 2025). But the existing literature on the pharmaceuticals often refer to the absolute need for the very close "symbiotic relationship" between algorithmic software automation and the clinical expertise of humans. There is a clear need for clinical pharmacists to continue to closely monitor all A.I. recommendations to ensure that they are clinically valid and take proactive measures to reduce any potential algorithmic bias, especially when dealing with very complex drug-drug interactions or when renally adjusting the dose for vulnerable geriatric patients (Gajarawala & Pelkowski, 2021). But some of the biggest challenges that stand in the way of AI's broad and global use in healthcare are workflow misalignment, limited technical interoperability concerns, and the staggering data privacy issues that come with the management of sensitive electronic health records. Hence, modern

pharmaceutical research has focused more than ever on the role of full integration of care models where AI is used only as an advanced digital triage and education tool, intentionally and intentionally designed to continually support, rather than mistakenly try to substitute, the core, legally mandated pharmacist-patient relationship (Fernandez-Lazaro et al., 2019).

The theoretical and conceptual rationales for the role of AI in the practice of pharmacy are very strong and convincing, but there is limited direct evidence from the literature to support long-term, measurable improvements in actual clinical parameters. Unfortunately, many of the clinical trials that exist have been conducted over short timeframes, in simulated non-clinical situations, and/or using mostly subjective, self-reported measures of medication adherence, which often have significant recall bias built right in (Kripalani et al., 2009). A very clear and well recognised deficiency in the literature exists for longitudinal, adequately powered randomized controlled trials that directly measure key behavioural outcomes (including Patient Activation Measure and Proportion of Days Covered) alongside highly objective clinical measures (such as glycated haemoglobin and systolic blood pressure). The present academic research is an attempt at addressing this specific and glaring gap in literature which tracks the dual synergistic effect of an adaptive AI educational intervention on both psychological engagement as well as physiological outcomes over the course of an extended, continuous twelve-month period within a highly realistic, real-life clinical pharmacy context.

Research Methodology

Current research was carefully planned and implemented as a prospective, multi-center, double-blinded randomized controlled study, carried out throughout a full 12-month evaluation period. The study protocol was very structured and was implemented in strict compliance with the ethical guidelines set forth worldwide in the Declaration of Helsinki and formal institutional review board (IRB) approval was obtained before any patient screening or recruitment was conducted. The clinical study was strategically placed within a large highly collaborative network of integrated health-system clinics and high-volume community pharmacies with a socioeconomically diverse patient population, capturing a typical and representative real world pharmacy work environment. The main goal of the methodology was to statistically and carefully assess the significant effect of an adaptive patient education platform based on artificial intelligence algorithms for patient activation, objective medication adherence, and ultimate clinical outcomes, while maintaining the digital intervention as unobtrusive as possible and easily integrated within the existing daily operational workflow of the recruited clinical pharmacists.

The selected study population was adult patients (age 18 years and older) with clinically diagnosed and officially diagnosed type 2 diabetes mellitus and primary hypertension by licensed physician. Highly strict inclusion criteria were applied at all clinical sites, to ensure the AI intervention was targeted appropriately to the most suitable and highest need population. Participants had to be taking at least two medications for the above chronic conditions for maintenance at the time of the study, and explicitly demonstrate a baseline medication non-adherence profile, highly objectively defined as less than 80 percent Proportional Days Covered (PDC) over the previous 6 month period (Caballero et al., 2023). Rigorous criteria included: any severe cognitive impairment documented; end-stage renal disease requiring hemodialysis; active psychiatric instability; and the inability to use standard mobile digital communications devices. A total of 301 highly eligible participants were successfully recruited and sequentially computer-generated to the artificial intelligence intervention group or standard care control group in a 1:1 ratio throughout the participant enrollment process. All participants gave formal written informed consent after a very comprehensive and easy-to-understand explanation of the study's purpose, risks, and procedures.

Patients assigned to the standard care control group were provided with very traditional and accepted “one size fits all” pharmaceutical care services. This is a standard care model, heavily incorporating standard medication dispensing procedures, a required first medication counseling session with the licensed clinical pharmacist, and the traditional provision of highly static and printed information educational sheets about disease state management, dietary restrictions and basic drug information. In contrast, the patients in the experimental group were completely immersed in the new artificial intelligence-based personalized patient education system. This sophisticated software platform made extensive use of deep neural networks and advanced natural language processing (NLP) to continually generate highly personalised learning materials, nudges and medication reminders and send them straight to the patient's own mobile phone using secure short message service and via a user-friendly mobile application (Ridho et al., 2022). The AI system also automatically, independently and constantly analyzed massive amounts of individual data from patients,

including secure data from the pharmacy management system about when patients had refilled their medication, sophisticated demographic information, and the patient's answers to the interactive digital queries on the side effects of the drugs. This ongoing data stream was used to dynamically tailoring the exact frequency, comprehension level and motivational psychological mood of the educational material, based exclusively on this stream of data.

Most importantly, a very structured workflow-based system was used to develop the artificial intelligence intervention, carefully crafted to support, not hinder, the pharmacist's time-consuming clinical workload. One of the most prominent aspects of the integrated system was a predictive analytics dashboard that was seamlessly embedded and directly connected to the pharmacy's electronic health record system. The machine learning algorithm ran independently for standard educational reinforcement and daily adherence monitoring, but specifically programmed to alert the health-care team to high-risk patients who had persistent high-risk adherence patterns or declining activation scores over time (Bates et al., 2024). If a patient's predicted trajectory was strongly suggestive of imminent severe clinical change, the artificial intelligence system immediately sent the clinical pharmacist a high priority, actionable alert, prompting a direct telepharmacy consultation to the patient or an urgent clinical intervention. This very advanced digital triage process meant that the precious limited human clinical knowledge was used with great efficiency and in a targeted way for the most complicated and vulnerable cases, thus increasing the overall value of the entire evaluated population, while decreasing alert fatigue and increasing patient safety.

Clinical data were collected systematically and stringently at four different time periods defined a priori: baseline, 3 months, 6 months and 12 months after randomization. Psychological patient engagement and objective medication adherence were the main behavioral outcomes that were continuously assessed. Precise measurement of patient engagement was then achieved through the highly validated 13 item Patient Activation Measure (PAM-13) which systematically produces a continuous psychometric score of zero to one hundred, which can then be divided into four progressively higher levels of clinical activation (Hibbard et al., 2004). The highly recognized Proportion of Days Covered was heavily assessed as an objective measure of medication adherence by accurately dividing the days the patient had physical medication by the total number of days in the assigned observation period. Secondary, objective clinical outcomes were glycated hemoglobin levels as precisely measured by standard laboratory venipuncture, and systolic blood pressure, as accurately measured by calibrated automated oscillometric sphygmomanometers at scheduled clinical visits. All advanced statistical analyses were carefully conducted using SPSS software, with an accurate evaluation of any long-term changes in scores over time using repeated measures analysis of variance, and multivariate logistic regression was used to appropriately control for various potential demographic factors.

Results and Discussion

Results from the full 12-month period of clinical data collection were analyzed using a detailed and rigorous statistical method and showed significant, highly statistically significant differences between the AI intervention group and the standard care control group for all behavioral and clinical parameters measured. A systematic analysis of the base-line demographic and clinical characteristics of the 301 formally enrolled participants was carefully conducted to assure extremely balanced distribution of the comparative groups. As presented in Table 1, the study population was extremely statistically homogeneous at baseline. Mean age was around 58 years with a very balanced distribution of participants by sex and baseline characteristics were exactly the same for the primary behavioral outcome (the Patient Activation Measure) and the secondary behavioral outcome (the Proportion of Days Covered). Moreover, basic clinical markers such as glycated hemoglobin and systolic blood pressure strongly suggested poor control and dangerous chronic disease conditions for both groups, clearly supporting the absolute need to target the chosen patient population for an intensive, adherence-oriented digital intervention.

Table 1: Baseline Demographic and Clinical Characteristics of the Study Population

Parameter	AI Intervention Group (n=150)	Standard Care Group (n=151)	p-value
Age (years)	58.2 ± 6.4	57.9 ± 6.7	0.68
Female (%)	52.60%	53.40%	0.89
Baseline PAM Score	54.2 ± 8.1	53.8 ± 8.4	0.67
Baseline PDC (%)	58.1 ± 10.2	57.6 ± 9.8	0.65
Baseline HbA1c (%)	8.8 ± 1.1	8.7 ± 1.2	0.45

Baseline SBP (mmHg)	148.5 ± 12.4	147.9 ± 11.8	0.66

The systematic long-term monitoring of behavioral indicators clearly and strongly showed a significant difference between the two groups assessed that developed quickly, held long, and had a deep impact. A deep psychological activation was achieved and proved by the comprehensive result analysis of the parameters of the Patient Activation Measure, through the highly adaptive Artificial Intelligence platform. The experimental intervention group showed a large, highly significant increase in the PAM score by the 3-month mark (54.2 to 68.5) which shifted the majority of the group from a very passive position to one of active knowledge acquisition and behavioral preparation. This impressive upward trend continued during the entire course of the study and ended with a very high mean score at the 12-month follow-up assessment of 78.4. By contrast, the standard care group showed very little activation, with only a minimal and not statistically significant change from a mean score of 60.0 at the start to a score of 59.2 at the end of the clinical study. At the same time, the very objective assessment of medication-taking—Proportion of Days Covered—was a perfect reflection of this large behavioural activation. By the end of the trial, the AI group's adherence rate reached 86.2%, a significantly better rate than a dangerous 58.1%, and a therapeutically effective level. Medication adherence in the control group was also significantly low, with only 62.8% achieved, and thus the participants continued to be at high risk of clinical complications.

The deep, well-documented behavioral adherence changes that directly followed the dynamic artificial intelligence model, were then highly predictably reflected in substantial and statistically significant decreases in pathological clinical markers. Table 2 is an extensive report of the comparative clinical results throughout the 12-month assessment period. Glycated hemoglobin levels in the intervention group steadily dropped and were quite significant, with a mean of 7.1% at month twelve, significantly closer than the generally accepted, ideal therapeutic target for tight diabetic management. This is an incredible absolute reduction of 1.7% which represents life-saving. The standard care group had a slight (but statistically insignificant) decrease of only 0.5%, ending at 8.2%. Likewise, the intervention group had a dramatic and significant drop in their systolic blood pressure from 148.5 to a very safe average of 128.6, which is considered normotensive. In the standard control group, there was very little clinically meaningful improvement; the SBP ended up dangerously high at 142.1 mmHg and they remained very vulnerable to cardiovascular events.

Table 2: Comparison of Clinical Outcomes and Adherence Metrics Between AI Intervention and Standard Care Groups Over 12 Months

Metric	Time Point	AI Intervention	Standard Care	p-value
PAM Score	3 Months	68.5	56.1	< 0.001
	6 Months	75.8	58.4	< 0.001
	12 Months	78.4	59.2	< 0.001
PDC (%)	3 Months	74.3	61.2	< 0.001
	6 Months	83.6	63.5	< 0.001
	12 Months	86.2	62.8	< 0.001
HbA1c (%)	3 Months	8.1	8.5	< 0.05
	6 Months	7.5	8.3	< 0.01
	12 Months	7.1	8.2	< 0.001
SBP (mmHg)	3 Months	139.2	145.1	< 0.05
	6 Months	132.4	143.8	< 0.01
	12 Months	128.6	142.1	< 0.001

The detailed analysis of these specifically analyzed clinical parameters strongly underlines a strong and highly sequential causal relationship, whereby the artificial intelligence intervention has been directly involved. Comprehensively and precisely synthesized by cutting-edge NLP algorithms, the adaptive educational nudges were found to effectively and sustainably break the deeply embedded individual psychological barriers to chronic disease management, clearly demonstrated by the acute and rapid increase of the Patient Activation Measure scores in the first 90 days of the trial. This is a very powerful psychological empowerment that strongly reinforced highly disciplined, daily behavioral routines, explicitly evident in the dramatic, sustained increase in the metric "Proportion of Days Covered" (Kearns et al., 2020). The physiological expression of this strict compliance with medication is predictable, mathematically produced and scientifically proven to be highly effective when actually taken as prescribed in medication specific to type 2 diabetes and hypertension.

Both glycated hemoglobin and systolic blood pressure parameters are in absolute normal range, clearly showing that well-designed artificial intelligence can not only be a mere novelty; it can be a highly critical therapeutic catalyst in modern medicine that saves lives (Ridho et al., 2022).

Moreover, the clinical study is an overwhelming success in terms of operations, and validates the tremendous, undeniable benefits of a workflow-driven software design. The current programmatic analysis dashboard proved to be a powerful tool and positively identified and accurately predicted 42 cases of impending severe non-adherence relapse in the intervention group well in advance of the clinical deterioration, for the entirety of the 12-month period. The AI system effectively served as an advanced digital triage system, efficiently maximizing the use of human resources in the pharmacy (Hatzimanolis et al., 2025). The pharmacists were found to be very satisfied with the system, particularly in terms of the massive amount of unnecessary and very inefficient follow up calls involving patients, which the system eliminated, they reported. The findings are extremely deep and well correlate with new studies and literature that have emerged in recent years and were peer-reviewed, which indicates that AI should never be used to replace the licensed pharmacist but rather must be used to complement their specific skills, by quickly pointing to huge amounts of clinical data and providing much more actionable and real-time clinical guidance (Gupta & Mehta, 2022). Patient education in deeply learned care and highly targeted clinical intervention by a pharmacist is a very successful convergence that is extremely sustainable and globally scalable indeed and can be seen as a blueprint for the absolute future of the modern pharmaceutical care.

Conclusion

The level of success that took an adaptive patient education platform with AI at the core and seamlessly integrated it into clinical pharmacy practice indisputably points to a powerful, undeniable impact in tackling this global, persistent and dangerous challenge of inadequate medication adherence. This careful and rigorous longitudinal research clearly demonstrates that, when correctly and carefully integrated (and strictly adhered to) within the current clinical workflow, advanced machine learning algorithms can continuously and dynamically respond to the individual psychology of each patient, and can rapidly bring about large and significant enhancements in health engagement as measured scientifically by the PATIENT ACTIVATION MEASURE. This level of activation directly prompted a significant and dramatic escalation in objective medication adherence with predictable highly statistically significant, life-saving reductions in glycated hemoglobin and systolic blood pressure over an extended period of 12 months each. The artificial intelligence system was able to successfully scale the pharmacist intervention in a seamless manner that delivered routine educational reinforcement and precisely identified non-adherence risks with high accuracy, thus allowing the delivery of highly specialized, expensive human care in an efficient manner and only to the most vulnerable, high-risk patient groups. Integrated healthcare systems and global pharmaceutical policymakers are strongly and unequivocally recommended to put accelerated priority on the rapid development, funding and clinical deployment of such highly validated, workflow-centered AI models. Future academic studies should focus heavily on rapidly expanding these proven digital interventions to much larger and highly diverse multicenter populations and rigorously evaluating the enormous long-term financial benefits from prevention of entirely, non-adherence-related, acute hospitalizations. In the end, the very successful, evidence-based melding of AI and the pharmaceutical care landscape is an truly critical and inevitable progression toward highly personalized, deeply proactive and universally equitable global chronic disease management.

List of References

- Backes, C., Moyano, C., Rimaud, C., Bienvenu, C., & Schneider, M. P. (2021). Digital medication adherence support: could healthcare providers recommend mobile health apps?. Frontiers in Medical Technology, 2, 616242.
- Bates, D. W., & Singh, H. (2024). Artificial intelligence applications in pharmacy to enhance medication adherence. American Journal of Health-System Pharmacy, 81(12), 1012-1018.
- Caballero, J., Patel, N., Waldrop, D., & Ownby, R. L. (2023). Patient activation and medication adherence in adults. Journal of the American Pharmacists Association, 63(1), 112-118.
- Conway, C. M., & Kelechi, T. J. (2017). Digital health for medication adherence in adult diabetes or hypertension: an integrative review. JMIR Diabetes, 2(2), e8030.
- Dima, A., Nabergoj-Makovec, U., & van Boven, J. M. (2024). Digital tools and medication adherence. Drug Utilization Research: Methods and Applications, 419-427.

- Fernandez-Lazaro, C. I., García-González, J. M., Adams, D. P., Fernandez-Lazaro, D., Mielgo-Ayuso, J., Caballero-Garcia, A., ... & Cordova, A. (2019). Adherence to treatment and related factors among patients with chronic conditions in primary care: a cross-sectional study. BMC Family Practice, 20(1), 132.
- Gajarawala, S. N., & Pelkowski, J. N. (2021). Telehealth benefits and barriers. The Journal for Nurse Practitioners, 17(2), 218-221.
- Ghozali, M. T., & Forthwengel, G. (2024). Design, Development, and Usability Testing of a Mobile app for Medication reminder among patients with Chronic conditions. Research Journal of Pharmacy and Technology, 17(5), 2146-2154.
- Gupta, A., & Mehta, V. (2022). Key obstacles in AI implementation: data privacy concerns, regulatory issues, and limitations in model accuracy. Journal of Medical Internet Research, 24(5), e33012.
- Hartani, N. H. (2022). The potential of digital health technologies in improving adherence to medication regimens among elderly patients. Archives of Clinical Psychiatry, 49(3).
- Hatzimanolis, A., Karagiannis, D., & Papadopoulos, E. (2025). Applications of artificial intelligence in current pharmacy practice: a scoping review. Research in Social and Administrative Pharmacy, 21(3), 415-422.
- Hibbard, J. H., Stockard, J., Mahoney, E. R., & Tusler, M. (2004). Development of the Patient Activation Measure (PAM): conceptualizing and measuring activation in patients and consumers. Health Services Research, 39(4p1), 1005-1026.
- Husnawati, H., Sukandar, E. Y., & Anggadiredja, K. (2022). Medication adherence and characteristics of hypertensive patients: a study in rural areas. Research Journal of Pharmacy and Technology, 15(1), 370-374.
- Kearns, R., Ciesla, M., & Craig, P. (2020). Implementing the Patient Activation Measure (PAM) in clinical settings for patients with chronic conditions: a scoping review. Integrative Healthcare Journal, 2(1), e000032.
- Kripalani, S., Risser, J., Gatti, M. E., & Jacobson, T. A. (2009). Development and evaluation of the Adherence to Refills and Medications Scale (ARMS) among low-literacy patients with chronic disease. Value in Health, 12(1), 118-123.
- Mathew, A. C., Aneesa, M. V., Rehman, A., Suresh, D., Suriyaprakash, T. N. K., & Joy, S. P. (2020). Assessment of medication adherence patterns and various causes of non-adherence in long term therapies in a tertiary care hospital. Research Journal of Pharmacy and Technology, 13(5), 2420-2426.
- O'Hara, D. V., Yi, T. W., Lee, V. W., Jardine, M., & Dawson, J. (2022). Digital health technologies to support medication adherence in chronic kidney disease. Nephrology, 27(12), 917-924.
- Ridho, A., Alfian, S. D., van Boven, J. F., Levita, J., Yalcin, E. A., Le, L., ... & Pradipta, I. S. (2022). Digital health technologies to improve medication adherence and treatment outcomes in patients with tuberculosis: systematic review of randomized controlled trials. Journal of Medical Internet Research, 24(2), e33062.
- Singh, H., Sharma, P., & Patel, K. (2024). AI-powered chatbots managing chronic diseases, enhancing medication adherence, and decreasing hospital readmissions. International Journal of Pharmaceutical Sciences, 16(4), 112-119.
- Zhang, L., Wang, Y., & Chen, H. (2023). Reduction in administrative tasks within pharmacies that implemented AI-integrated systems. Journal of Medical Internet Research, 25(1), e40167.
- Whalley Buono, E., Vrijens, B., Bosworth, H. B., Liu, L. Z., Zullig, L. L., & Granger, B. B. (2017). Coming full circle in the measurement of medication adherence: opportunities and implications for health care. Patient Preference and Adherence, 11, 1009-1017.

Works cited

1. Impact of Digital Health Technologies on Medication Adherence, https://ajpsonline.com/AbstractView.aspx?PID=2025-15-2-7
2. AI-Driven Chatbots and Virtual Assistants in Pharmaceutical Care, https://www.ijpsjournal.com/article/AI%20Driven%20Chatbots%20and%20Virtual%20Assistants%20in%20Pharmaceutical%20Care%20A%20Comprehensive%20Review
3. Patient activation, adherence to hypertension treatment plans and, https://pmc.ncbi.nlm.nih.gov/articles/PMC9884875/
4. (PDF) Implementing the Patient Activation Measure (PAM) in clinical, https://www.researchgate.net/publication/342672531_Implementing_the_Patient_Activation_Measure_

PAM_in_clinical_settings_for_patients_with_chronic_conditions_a_scoping_reviewImplementing_the_Patient_Activation_Measure_PAM_in_clinical_settings_for_patie
5. Patient activation and medication adherence in adults, https://scholars.nova.edu/en/publications/patient-activation-and-medication-adherence-in-adults
6. Coming full circle in the measurement of medication adherence, https://pdfs.semanticscholar.org/8253/7fc47fc144158a939d86416a38066cfae21c.pdf
7. Applications of artificial intelligence in current pharmacy practice, https://www.researchgate.net/publication/387151333_APPLICATIONS_OF_ARTIFICIAL_INTELLIGENCE_IN_CURRENT_PHARMACY_PRACTICE_A_SCOPING_REVIEW
8. Effects of a medication adherence app among ... - PMC - NIH, https://pmc.ncbi.nlm.nih.gov/articles/PMC11026187/
9. (PDF) Artificial intelligence applications in pharmacy to enhance, https://www.researchgate.net/publication/407440138_Artificial_intelligence_applications_in_pharmacy_to_enhance_medication_adherence_and_improve_patient_outcomes
10. The Role of AI-Based Clinical Decision Support Systems (AI-CDSS, https://rsisinternational.org/journals/ijriss/uploads/vol9-iss10-pg801-804-202511_pdf.pdf